These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 25670221)

  • 1. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
    Shah A; Mangaonkar A
    Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
    Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.
    Hewett YG; Uprety D; Shah BK
    J Oncol Pharm Pract; 2016 Apr; 22(2):284-8. PubMed ID: 25712626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
    Davies A
    Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
    Smolewski P; Rydygier D
    Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 13. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
    Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
    Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
    Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idelalisib: first global approval.
    Markham A
    Drugs; 2014 Sep; 74(14):1701-7. PubMed ID: 25187123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idelalisib approved for three blood cancers.
    Traynor K
    Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
    [No Abstract]   [Full Text] [Related]  

  • 20. GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.
    Macias-Perez IM; Flinn IW
    Curr Hematol Malig Rep; 2013 Mar; 8(1):22-7. PubMed ID: 23114654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.